Tanvex BioPharma, Inc., Taiwan-based biosimilar-focused biopharmaceutical company and a contract development and manufacturing organisation (CDMO) has announced that its Board of Directors has appointed Stephen Lam as the company's Chief Executive Officer, effective September 5, 2024. Lam succeeds Henry Chen, who shall remain the Chairman until the closing of Tanvex’s strategic alliance with Bora Pharmaceuticals.

As a part of the new leadership initiated by Bora, Lam will be responsible for ensuring a successful integration, driving the company’s strategic initiatives as well as overseeing Tanvex's day-to-day operations, including its global CDMO operations and the commercialisation of its biosimilar pipeline.

With over 35 years in the biopharmaceutical industry at leading companies including Lonza, Amgen, and Patheon, Lam has built a strong track record of delivering results. More recently, he served as Vice President and General Manager, Head of Biologics at Thermo Fisher Scientific.

“His extensive experience in biologics operations and proven track record of driving operational excellence will be instrumental to advancing our CDMO capabilities. As a key aspect of our alliance with Bora, this appointment will help the company expand its global presence and accelerate its growth, thereby taking Tanvex to new heights”, said Henry Chen.